Impact of hydroxyurea on clinical events in the BABY HUG trial.

  title={Impact of hydroxyurea on clinical events in the BABY HUG trial.},
  author={Courtney D Thornburg and Beatrice A Files and Zhaoyu Luo and Scott T. Miller and Ram V. Kalpatthi and Rathi V Iyer and Phillip Seaman and Jeffrey D Lebensburger and Ofelia A Alvarez and Bruce W. Thompson and Russell E Ware and Winfred C. Wang},
  volume={120 22},
  pages={4304-10; quiz 4448}
The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninety-three subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 58 extracted citations


Publications referenced by this paper.
Showing 1-10 of 40 references

Similar Papers

Loading similar papers…